The Sinovac vaccine is one of at least five Chinese shots undergoing late-stage trials.
The coronavirus vaccine developed by Chinese company Sinovac Biotech was found to be 78% effective in late-stage trials in Brazil, Brazilian media reported Thursday.
Sao Paulo’s Butantan Institute — Sinovac’s Brazilian partner — had submitted a request for the shot’s emergency use.
The trial results bring the vaccine, called CoronaVac, one step closer to being cleared for use in South America’s largest country, which also has the continent’s highest number of COVID-19 cases.
Trials for vaccines developed by Moderna and BioNTech-Pfizer were found to be 90% effective. However, Sinovac’s jab is said to be easier to transport and can be stored at normal refrigerator temperatures. Brazil is hoping to begin administering the company’s vaccine this month. Indonesia, Turkey, Chile, Singapore, Ukraine and Thailand have also struck deals with the firm.
Meanwhile, the World Health Organization (WHO) said Thursday it was reviewing “some vaccines from China” and the vaccine developed by AstraZeneca and Oxford University for possible emergency listing.